Britain and America have agreed to a important trade agreement that will ensure zero import taxes on UK pharmaceutical exports being sold in the US market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to increase spending on drugs through the public health system. This move secures that tariffs on these key exports will be held at zero for a duration of 36 months.
This development comes after earlier statements to significantly raise duties on patented drug products, with increases floated up to one hundred percent.
"This deal with the Britain bolsters the global environment for cutting-edge drugs and establishes much-needed balance to transatlantic pharmaceutical trade," an announcement said.
Trade Impact
Pharmaceuticals are one of the UK's biggest export categories to the America, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Export figures show that in the one-year period leading up to September, the UK shipped drugs worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of British export trade in that period.
"This agreement protects jobs, stimulates funding and sets the stage for the UK to become a global hub for life sciences," a minister commented.
Key UK Commitments
The deal involves several specific commitments from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to raise total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments exceeded 20%.
Broader Context
The pact comes amid a protracted tension between the sector and the British authorities over spending levels and NHS adoption.
The disagreement were heightened by claims that American customers were paying a premium for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while substantial expansions have been directed toward American operations.
One official publicly accepted that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the past decade.
